Botanical species · safety record

Sauropus androgynus

The EFSA Compendium of Botanicals holds 1 constituent measurement and 3 adverse-effect records for Sauropus androgynus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Sauropus androgynus (L.) Merr.

1Constituent measurements
3Safety records
3Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Lignans1

Plant parts

  • Leaves3
  • Aerial part of plants1

Preparations

  • Solvent extraction1

Effect types

  • Pulmonary and cardiac3

Target tissues

  • Lung3

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
LignansAerial part of plantsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
Pulmonary and cardiacLungLeavesHuman (as organism)Case reportResolve DOI
Pulmonary and cardiacLungLeavesHuman (as organism)Case reportResolve DOI
Pulmonary and cardiacLungLeavesHuman (as organism)Study with volunteersNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Luh, SP., Lee, YC., Chang, YL., Wu, HD., Kuo, SH., Chu, SH. Lung transplantation for patients with end-stage Sauropus androgynus-induced bronchiolitis obliterans (SABO) syndrome . Clinical transplantation, 1999, vol. 13, no. 6, p. 496-503. DOI
  2. Kanchanapoom, T., Chumsri, P., Kasai, R., Otsuka, H., Yamasaki, K. Lignan and megastigmane glycosides from Sauropus androgynus. Phytochemistry, 2003, vol. 63, no. 8, p. 985-988. DOI
  3. Ger, LP., Chiang, AA., Lai, RS., Chen, SM., Tseng, CJ. Association of Sauropus androgynus and bronchiolitis obliterans syndrome: A hospital-based case-control study . American journal of epidemiology, 1997, vol. 145, no. 9, p. 842-849.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue